Notably, BIRC5 and FOXM1 expression was also reduced in taxane-treated breast cancer patients (Figure 6), and FOXM1 expression was upregulated in most of the PTXR TNBC cell lines (Figure 5F) consistent with its established role in drug resistance to genotoxic agents, such as taxane and epirubicin [27]. The gene discussed is FOXM1; the disease is breast carcinoma.